Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trial

Lindsey E. Roeker, Jennifer A. Woyach, Chan Y. Cheah, Catherine C. Coombs, Nirav N. Shah, William G. Wierda, Manish R. Patel, Nicole Lamanna, Donald E. Tsai, Binoj Nair, Chunxiao Wang, Xiang Zhao, Dan Liu, David Radtke, Sonya Chapman, Narasimha Marella, Samuel C. McNeely, Jennifer R. Brown

Blood (2024) 144 (13): 1374–1386.

https://doi.org/10.1182/blood.2024024510

Published: 2024

Includes: Supplemental data

Journal Articles

Pirtobrutinib in Post-cBTKi CLL/SLL: ~30 Months Follow-up and Subgroup Analysis With/Without Prior BCL2i from the Phase 1/2 BRUIN Study

Blood (2023) 142 (Supplement 1): 325.

https://doi.org/10.1182/blood-2023-185852

Published: 2023

Journal Articles

Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Marginal Zone Lymphoma: Results from Phase 1/2 BRUIN Study

Blood (2023) 142 (Supplement 1): 1660.

https://doi.org/10.1182/blood-2023-180048

Published: 2023

Journal Articles

Pirtobrutinib in Richter Transformation: Updated Efficacy and Safety Results with 18-Month Median Survival Follow-up from the Phase 1/2 BRUIN Study

Blood (2023) 142 (Supplement 1): 1737.

https://doi.org/10.1182/blood-2023-181108

Published: 2023

Journal Articles

Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed/Refractory Follicular Lymphoma: Results from the Phase 1/2 BRUIN Study

Blood (2023) 142 (Supplement 1): 3026.

https://doi.org/10.1182/blood-2023-181309

Published: 2023

Journal Articles

Fixed-Duration Pirtobrutinib Combined with Venetoclax ± Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia: Updated Results, Including MRD Data, from the BRUIN Phase 1b Study

Lindsey E. Roeker, Jennifer A. Woyach, Chan Y. Cheah, Catherine C Coombs, Nirav N. Shah, William G. Wierda, Manish Patel, Donald E. Tsai, Binoj Nair, Chunxiao Wang, Xiang Zhao, Narasimha Marella, Caleb Ho, Samuel McNeely, Jennifer R. Brown

Blood (2023) 142 (Supplement 1): 3269.

https://doi.org/10.1182/blood-2023-181090

Published: 2023

Journal Articles

Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) Patients with Prior cBTKi: Safety and Efficacy Including High-Risk Subgroup Analyses from the Phase 1/2 BRUIN Study

Blood (2023) 142 (Supplement 1): 981.

https://doi.org/10.1182/blood-2023-181627

Published: 2023

Journal Articles

Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory CLL/SLL: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study

Blood (2022) 140 (Supplement 1): 2316–2320.

https://doi.org/10.1182/blood-2022-159497

Published: 2022

Journal Articles

Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study

Blood (2022) 140 (Supplement 1): 9368–9372.

https://doi.org/10.1182/blood-2022-159425

Published: 2022

Journal Articles

Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Richter Transformation: Results from the Phase 1/2 BRUIN Study

Blood (2022) 140 (Supplement 1): 846–849.

https://doi.org/10.1182/blood-2022-157058

Published: 2022

Journal Articles

Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Waldenström Macroglobulinemia: Results from the Phase 1/2 BRUIN Study

Blood (2022) 140 (Supplement 1): 557–560.

https://doi.org/10.1182/blood-2022-159123

Published: 2022

Journal Articles

Results from a First-in-Human, Proof-of-Concept Phase 1 Trial in Pretreated B-Cell Malignancies for Loxo-305, a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor

Anthony R. Mato, MDMSCE, Ian W. Flinn, MD PhD, John M. Pagel, MD PhD DSc, Jennifer R. Brown, MD PhD, Chan Y. Cheah, Catherine C. Coombs, MD, Manish R. Patel, MD, S. Michael Rothenberg, MD PhD, Donald E. Tsai, MD PhD, Nora C. Ku, MD, Michael L. Wang, MD

Blood (2019) 134 (Supplement_1): 501.

https://doi.org/10.1182/blood-2019-127509

Published: 2019

Journal Articles

Long-Term Outcomes of Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disorder (EBV + PTLD) Following Solid Organ (SOT) or Allogeneic Hematopoietic Cell Transplants (HCT) Treated with Tabelecleucel on an Expanded Access Program

Susan Prockop, MD, Ran Reshef, MDMSc, Donald E. Tsai, MD PhD, Nancy Bunin, MD, Rolla Abu-Arja, MD, Kris Michael Mahadeo, MD, Wen-Kai Weng, MD PhD, Koen Van Besien, MD PhD, David Loeb, MD PhD, Sunita Dwivedy Nasta, MD, Eneida R. Nemecek, MDMBA,MSc, Minoti Hiremath, MBBS, PhD, Susan Yue, MD, Yan Sun, PhD, Willis Navarro, MD, Sarah Nikiforow, MD PhD

Blood (2019) 134 (Supplement_1): 4071.

https://doi.org/10.1182/blood-2019-124904

Published: 2019

Journal Articles

Receipt of Maintenance Therapy Is Most Predictive of Survival in Older Acute Lymphoblastic Leukemia Patients Treated with Intensive Induction Chemotherapy Regimens.

Daniel J. Landsburg, MD, Edward A. Stadtmauer, MD, Alison W. Loren, MD, Steven C. Goldstein, MD, Noelle V. Frey, MD, Sunita D. Nasta, MD, David L Porter, MD, Donald E Tsai, MD PhD, Alexander E Perl, MD, Elizabeth Hexner, MD, Selina Luger, MD

Blood (2012) 120 (21): 2600.

https://doi.org/10.1182/blood.V120.21.2600.2600

Published: 2012

Journal Articles

A Phase I Clinical Trial Using Eltrombopag in Patients with Acute Myelogenous Leukemia

Noelle V. Frey, MD, Elizabeth O. Hexner, MD, David L Porter, MD, James K. Mangan, MD, PhD, Alison W. Loren, MD, Joseph Hatem, MD, Adam Bagg, MD, Alexander E Perl, MD, Donald E Tsai, MD PhD, Courtney D. DiNardo, MD, Daniel Heitjian, PhD, Selina M. Luger, MD, Martin Carroll, MD

Blood (2012) 120 (21): 3576.

https://doi.org/10.1182/blood.V120.21.3576.3576

Published: 2012

Journal Articles

Posttransplant Lymphoproliferative Disorder in Kidney Transplant Patients: A Report of 68 Cases

Kathleen J Tsai, Jonathan H Bloom, Ran Reshef, MD, Deirdre Sawinski, MD, Melissa Bleicher, MD, Simin Goral, MD, Robert Grossman, MD, Donald E Tsai, MD PhD, Roy D Bloom, MD

Blood (2011) 118 (21): 2662.

https://doi.org/10.1182/blood.V118.21.2662.2662

Published: 2011

Journal Articles

Reduction of Immunosuppression as Initial Therapy for Post-Transplantation Lymphoproliferative Disorder: Analysis of Efficacy, Safety and Prognostic Factors.

Ran Reshef, MD, Saran Vardhanabhuti, MS, Marlise R Luskin, MD, Daniel F Heitjan, PhD, David L Porter, MD, Edward A Stadtmauer, MD, Donald E Tsai, MD, PhD

Blood (2009) 114 (22): 103.

https://doi.org/10.1182/blood.V114.22.103.103

Published: 2009

Journal Articles

Combination Daclizumab and Infliximab for Steroid Refractory Acute Graft-Versus-Host Disease.

Alison Rager, MD, Steven C. Goldstein, MD, Noelle Frey, MD, Jennifer Davis, PharmD, Michael Vozniak, PharmD, Jacqueline Smith, Elizabeth Hexner, MD, Alison Wakoff Loren, MD, MS, Selina Luger, MD, Alexander Perl, MD, Ran Reshef, MD, Donald E Tsai, MD, PhD, Edward A. Stadtmauer, MD, David Porter, MD

Blood (2009) 114 (22): 4643.

https://doi.org/10.1182/blood.V114.22.4643.4643

Published: 2009

Journal Articles

EBV-Negative Post-Transplant Lymphoproliferative Disorder (PTLD): A Retrospective Case-Control Study of Clinical and Pathological Characteristics, Response to Treatment and Survival

Ran Reshef, MD, Alicia K. Morgans, MD, Nicklas R. Pfanzelter, MD, Roy D. Bloom, MD, Susan C. Brozena, MD, Vivek N. Ahya, MD, Kim M. Olthoff, MD, Donald E. Tsai, MD, PhD

Blood (2008) 112 (11): 2823.

https://doi.org/10.1182/blood.V112.11.2823.2823

Published: 2008

Journal Articles

A Phase II Trial of Bexarotene, a Retinoid X Receptor Agonist, in Non-M3 Acute Myeloid Leukemia

Donald E. Tsai, MD, PhD, Melissa Potuzak, BS, Anthony Mato, MD, Alison Wakoff Loren, MD, MS, David Porter, MD, Edward A. Stadtmauer, MD, Steven Goldstein, MD, Alexander Perl, MD, Cezary Swider, BS, Adam Bagg, MD, Emile Youssef, MD, PhD, Selina Luger, MD

Blood (2008) 112 (11): 4040.

https://doi.org/10.1182/blood.V112.11.4040.4040

Published: 2008

NARROW

Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trial

Pirtobrutinib in Post-cBTKi CLL/SLL: ~30 Months Follow-up and Subgroup Analysis With/Without Prior BCL2i from the Phase 1/2 BRUIN Study

Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Marginal Zone Lymphoma: Results from Phase 1/2 BRUIN Study

Pirtobrutinib in Richter Transformation: Updated Efficacy and Safety Results with 18-Month Median Survival Follow-up from the Phase 1/2 BRUIN Study

Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed/Refractory Follicular Lymphoma: Results from the Phase 1/2 BRUIN Study

Fixed-Duration Pirtobrutinib Combined with Venetoclax ± Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia: Updated Results, Including MRD Data, from the BRUIN Phase 1b Study

Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) Patients with Prior cBTKi: Safety and Efficacy Including High-Risk Subgroup Analyses from the Phase 1/2 BRUIN Study

Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory CLL/SLL: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study

Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study

Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Richter Transformation: Results from the Phase 1/2 BRUIN Study

Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Waldenström Macroglobulinemia: Results from the Phase 1/2 BRUIN Study

Results from a First-in-Human, Proof-of-Concept Phase 1 Trial in Pretreated B-Cell Malignancies for Loxo-305, a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor

Long-Term Outcomes of Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disorder (EBV + PTLD) Following Solid Organ (SOT) or Allogeneic Hematopoietic Cell Transplants (HCT) Treated with Tabelecleucel on an Expanded Access Program

Receipt of Maintenance Therapy Is Most Predictive of Survival in Older Acute Lymphoblastic Leukemia Patients Treated with Intensive Induction Chemotherapy Regimens.

A Phase I Clinical Trial Using Eltrombopag in Patients with Acute Myelogenous Leukemia

Posttransplant Lymphoproliferative Disorder in Kidney Transplant Patients: A Report of 68 Cases

Reduction of Immunosuppression as Initial Therapy for Post-Transplantation Lymphoproliferative Disorder: Analysis of Efficacy, Safety and Prognostic Factors.

Combination Daclizumab and Infliximab for Steroid Refractory Acute Graft-Versus-Host Disease.

EBV-Negative Post-Transplant Lymphoproliferative Disorder (PTLD): A Retrospective Case-Control Study of Clinical and Pathological Characteristics, Response to Treatment and Survival

A Phase II Trial of Bexarotene, a Retinoid X Receptor Agonist, in Non-M3 Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only